Hsbc Holdings PLC Has $9.94 Million Stock Position in STERIS plc $STE

Hsbc Holdings PLC lessened its stake in shares of STERIS plc (NYSE:STE) by 9.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,965 shares of the medical equipment provider’s stock after selling 4,094 shares during the quarter. Hsbc Holdings PLC’s holdings in STERIS were worth $9,943,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in STE. Board of the Pension Protection Fund acquired a new position in STERIS during the 4th quarter worth approximately $25,000. Activest Wealth Management grew its stake in STERIS by 423.8% in the fourth quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 89 shares during the period. Measured Wealth Private Client Group LLC bought a new stake in shares of STERIS during the fourth quarter valued at approximately $28,000. Harbor Investment Advisory LLC increased its holdings in shares of STERIS by 115.4% during the fourth quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 60 shares in the last quarter. Finally, Cornerstone Planning Group LLC raised its position in shares of STERIS by 342.3% during the fourth quarter. Cornerstone Planning Group LLC now owns 115 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 89 shares during the period. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on STE. Wall Street Zen cut STERIS from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 6th. Weiss Ratings downgraded shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 27th. Piper Sandler reaffirmed an “overweight” rating and issued a $270.00 price objective on shares of STERIS in a research note on Thursday, May 21st. Finally, KeyCorp reduced their price objective on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $278.00.

STERIS Price Performance

STE opened at $215.59 on Friday. STERIS plc has a 1 year low of $195.14 and a 1 year high of $269.44. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.09 and a quick ratio of 1.54. The company has a market capitalization of $21.01 billion, a price-to-earnings ratio of 27.19 and a beta of 0.93. The firm’s fifty day moving average price is $212.77 and its two-hundred day moving average price is $233.29.

STERIS (NYSE:STE) last announced its earnings results on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a net margin of 13.18% and a return on equity of 14.15%. The firm had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.59 billion. During the same quarter in the prior year, the company earned $2.74 EPS. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, analysts anticipate that STERIS plc will post 11.18 earnings per share for the current fiscal year.

STERIS Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 26th. Shareholders of record on Monday, June 8th were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend was Monday, June 8th. STERIS’s dividend payout ratio is presently 31.78%.

Insider Buying and Selling at STERIS

In other STERIS news, CEO Daniel A. Carestio sold 1,374 shares of STERIS stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $212.00, for a total transaction of $291,288.00. Following the transaction, the chief executive officer owned 63,647 shares of the company’s stock, valued at $13,493,164. This trade represents a 2.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP John Adam Zangerle sold 1,419 shares of STERIS stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $209.28, for a total transaction of $296,968.32. Following the transaction, the vice president directly owned 35,259 shares in the company, valued at approximately $7,379,003.52. This represents a 3.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 7,328 shares of company stock worth $1,554,051. Insiders own 1.12% of the company’s stock.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.